AGLE-102

N/A

Report date: 2024/01/12 15:46:47

First In Class

Base Information

Drug NameAGLE-102

Drug Alias NameMSC EVs细胞外囊泡疗法Extracellular vesicle therapy (Aegle Therapeutics)骨髓间充质干细胞衍生的细胞外囊泡Bone marrow mesenchymal stem cell derived extracellular vesicles (Aegle Therapeutics) +[7]

ClassificationBiologics > Extracellular VesiclesCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived

Mechanisms of ActionCollagenase replacements

TargetsCollagen

Therapy Area/IndicationsBurnsEpidermolysis Bullosa Dystrophica

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAegle Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesAegle Therapeutics

Inactive CompaniesN/A

Active IndicationsBurnsEpidermolysis Bullosa Dystrophica

Inactive IndicationsN/A

Other Information

ATC CodeN/A